Excelimmune, Inc.

Excelimmune, Inc. specializes in advanced diagnostics, particularly in developing innovative assays for detecting pathogens and toxins, enhancing public health safety through accurate molecular detection methods. Excelimmune, Inc. focuses on developing advanced diagnostic tools for pathogen detection.

The company is headquartered in Woburn, US. In January 2012, it raised USD 6 mn in VENTURE DEBT financing. The founder's information is not available, and there are no known pivots or subsidiary details. Excelimmune Immunity Reagents specializes in developing advanced diagnostic tools and assays for the molecular detection of pathogens and toxins.

Their primary products include Polymerase Chain Reaction (PCR) assays for infectious agents like the Zika virus and mycotoxins. Their offerings, such as the BioFire® FilmArray® BCID PCR Panel and BioFire® FilmArray® Respiratory Pathogen PCR Panel, are utilized by healthcare facilities, research institutions, and food safety organizations, significantly contributing to public health safety. Excelimmune Immunity Reagents generates revenue through direct-to-consumer and B2B sales of its diagnostic products and services. Clients, including hospitals and diagnostic laboratories, purchase items like the BioFire® FilmArray® PCR Panels through outright purchases or subscription agreements.

The pricing is based on the assay complexity, with flagship products like the GelRed (10,000X) nucleic acid stain contributing to the overall revenue stream. Excelimmune plans to use the USD 6 mn raised in VENTURE DEBT financing as part of their strategy for future growth. They are expected to launch new diagnostic products in the coming years, targeting expansion into additional markets across North America and Europe by 2025. The company aims to enhance its product offerings and increase market penetration to meet the rising demand for accurate diagnostics.